Dr. Chien-Shing Chen, MD

Dr. Chen practices at Loma Linda University Medical Center in Loma Linda, California, part of Seventh-day Adventist Church.

Dr. Chen's NPI, 1073542692, was assigned on July 3, 2006. Dr. Chen graduated from China Medical University (Taiwan) in 1985. Dr. Chen's California license number on file is A66192.

Dr. Chen's primary practice is Loma Linda University Medical Center, at 11234 Anderson St, Loma Linda, CA 92354 in San Bernardino County. The practice phone is (909) 558-4000.

Dr. Chen's primary practice is Loma Linda University Medical Center in Loma Linda, California, part of Seventh-day Adventist Church. The medical group on file is Loma Linda University Faculty Medical Group (LLUFMG). Dmand AI also links Dr. Chen to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Chen practices, 2 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Chen's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Chen is board certified in internal medicine by the American Board of Internal Medicine. Dr. Chen has a license on file in California.

Dmand AI lists breast cancer, chronic anemia, lung cancer, lymphoma, multiple myeloma, neutropenia, prostate cancer and purpura and thrombocytopenia among the conditions Dr. Chen treats.

CMS data shows 461 Medicare services from Dr. Chen across 4 procedure codes in 2024, for 167 Medicare patients. Medicare paid $30,135 for them.

CMS counts 167 Medicare patients who saw Dr. Chen in 2024. The largest group is 65 to 74, with 74 patients. 75% of them have high blood pressure, and 66% have high cholesterol. 29% are also on Medicaid. Their average risk score is 2.53, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Chen's median patient age at 67, with 45% women.

In 2024, Dr. Chen wrote 613 Medicare Part D claims for 76 patients. 62% of them were for generic drugs. CMS names the drug for 460 of them, across 15 drugs with 11 or more claims each, at $2,735,106 in total drug cost. In 2023, CMS named 325 claims across 13 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 89 out of 100 for Dr. Chen for performance year 2024, reported as part of a group. Dr. Chen accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Chen as offering telehealth.

Dmand AI links 73 papers to Dr. Chen, published from 2006 to 2024. 2015 was the busiest year, with 3. The most frequent topics are Cell Line, Tumor, Apoptosis and Leukemia, Myeloid, Acute. Dr. Chen has published most often in Blood. Dr. Chen's most frequent co-authors are Huynh Cao, MD, Mark Evan Reeves, MD and David Baylink, MD.

Dmand AI links Dr. Chen to 9 clinical trials, 3 of them phase 2 studies. 5 are still active or recruiting. Conditions studied include Leukemia, Myeloid, Acute, Burkitt Lymphoma and Gliosarcoma. National Cancer Institute (NCI) sponsors the most, 4.

CMS Open Payments shows 196 general payments to Dr. Chen from 27 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 56% of the total. Pharmacyclics LLC, An AbbVie Company paid the most, $29,428.

Dmand AI lists 1 award for Dr. Chen.

Dr. Chen graduated from China Medical University (Taiwan) in 1985. Dr. Chen is a member of ASCO.

Dr. Chen is in network with 14 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 9. Check the plan with the practice before a visit.